[
    [
        {
            "time": "2021-12-28",
            "original_text": "华东医药：子公司全资收购华昌高科 开拓工业微生物新领域",
            "features": {
                "keywords": [
                    "华东医药",
                    "全资收购",
                    "华昌高科",
                    "工业微生物"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华东医药：子公司全资收购华昌高科 开拓工业微生物新领域",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-28",
            "original_text": "加快工业微生物技术优势全球化产业发展 华东医药全资收购华昌高科",
            "features": {
                "keywords": [
                    "工业微生物",
                    "全球化",
                    "华东医药",
                    "全资收购"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "加快工业微生物技术优势全球化产业发展 华东医药全资收购华昌高科",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-28",
            "original_text": "华东医药(000963.SZ)：子公司中美华东拟收购破产重整后的华昌高科100%股权 关联方问题",
            "features": {
                "keywords": [
                    "华东医药",
                    "中美华东",
                    "破产重整",
                    "华昌高科",
                    "100%股权"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华东医药(000963.SZ)：子公司中美华东拟收购破产重整后的华昌高科100%股权 关联方问题",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-28",
            "original_text": "华东医药：参与华昌高科破产重整 收购其100%股权 减资破产",
            "features": {
                "keywords": [
                    "华东医药",
                    "破产重整",
                    "华昌高科",
                    "100%股权",
                    "减资"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华东医药：参与华昌高科破产重整 收购其100%股权 减资破产",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-28",
            "original_text": "华东医药今日大宗交易成交36万股，成交价38.7元溢价0.0%",
            "features": {
                "keywords": [
                    "华东医药",
                    "大宗交易",
                    "36万股",
                    "38.7元",
                    "溢价0.0%"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药今日大宗交易成交36万股，成交价38.7元溢价0.0%",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 5,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-12-28",
            "original_text": "天士力被收智商税？ 首付2.5亿元引入进度落后的FRα ADC",
            "features": {
                "keywords": [
                    "天士力",
                    "智商税",
                    "2.5亿元",
                    "FRα ADC",
                    "进度落后"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "天士力被收智商税？ 首付2.5亿元引入进度落后的FRα ADC",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]